Re-irradiation in patients affected by prostate cancer and relapsing after previous definitive or postoperative radiotherapy. An international registry based study on behalf of Italian association of radiotherapy and clinical oncology (AIRO). (RE-START)
Giulio Francolini , Vanessa Di Cataldo , Saverio Caini , Barbara A Jereczek-Fossa , Giulia Marvaso , Federico Mastroleo , Eugenio Cammareri , Daniela Alterio , Marcin Miszczyk , Wojciech Majewski , Maja Hasterok , Fabio Matrone , Alessandra Donofrio , Luca Triggiani , Vittorio Morelli , Liliana Belgioia , Elisa D’angelo , Rosario Mazzola , Rossana Ingargiola , Antonella Fontana , Lorenzo Livi
{"title":"Re-irradiation in patients affected by prostate cancer and relapsing after previous definitive or postoperative radiotherapy. An international registry based study on behalf of Italian association of radiotherapy and clinical oncology (AIRO). (RE-START)","authors":"Giulio Francolini , Vanessa Di Cataldo , Saverio Caini , Barbara A Jereczek-Fossa , Giulia Marvaso , Federico Mastroleo , Eugenio Cammareri , Daniela Alterio , Marcin Miszczyk , Wojciech Majewski , Maja Hasterok , Fabio Matrone , Alessandra Donofrio , Luca Triggiani , Vittorio Morelli , Liliana Belgioia , Elisa D’angelo , Rosario Mazzola , Rossana Ingargiola , Antonella Fontana , Lorenzo Livi","doi":"10.1016/j.radonc.2025.111138","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Aiming to evaluate the long-term safety of re-irradiation approaches, the Italian Association for Radiotherapy and Clinical Oncology Oncology (AIRO) re-irradiation study group proposed the institution of a multicentric registry including prostate cancer patients undergoing re-irradiation for local relapse after postoperative or definitive RT.</div></div><div><h3>Materials and methods</h3><div>RESTART is an observational longitudinal study including patients with biochemical relapse according to EAU criteria after a previous course of definitive or postoperative RT, and treated for a macroscopic recurrence within the prostate or prostate bed visualized on PET-CT or magnetic resonance imaging (MRI). Patients were treated with stereotactic body radiotherapy (SBRT) or brachytherapy (BT), with fraction doses of at least 5 Gy for EBRT, and no other restrictions regarding fractionation schedule or total dose. Exclusion criteria consisted of the presence of regional nodal disease or distant metastases, persisting severe toxicities from previous RT or follow-up shorter than 6 months.</div></div><div><h3>Results</h3><div>Four hundred and thirty-three patients from 5 centers were included in the current analysis. Overall, 64.2 % and 90.3 % of patients did not report any acuteGU or GI toxicity. No treatment-related deaths were registered. LateG2 or G3 GU toxicity was reported in 16.2 and 4.8 % of patients, respectively. After a median follow-up of 54 months (95 % CI 26–78), 239 biochemical recurrences (55.2 %), 119 radiologically-confirmed regional or distant relapses (27.2 %), and 95 deaths (21.9 %) were recorded, respectively.</div></div><div><h3>Conclusion</h3><div>Results confirm the safety, feasibility, and efficacy of re-irradiation for prostate cancer, and provide insights about features associated with improved oncological outcomes after treatment.</div></div>","PeriodicalId":21041,"journal":{"name":"Radiotherapy and Oncology","volume":"212 ","pages":"Article 111138"},"PeriodicalIF":5.3000,"publicationDate":"2025-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Radiotherapy and Oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0167814025046420","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background
Aiming to evaluate the long-term safety of re-irradiation approaches, the Italian Association for Radiotherapy and Clinical Oncology Oncology (AIRO) re-irradiation study group proposed the institution of a multicentric registry including prostate cancer patients undergoing re-irradiation for local relapse after postoperative or definitive RT.
Materials and methods
RESTART is an observational longitudinal study including patients with biochemical relapse according to EAU criteria after a previous course of definitive or postoperative RT, and treated for a macroscopic recurrence within the prostate or prostate bed visualized on PET-CT or magnetic resonance imaging (MRI). Patients were treated with stereotactic body radiotherapy (SBRT) or brachytherapy (BT), with fraction doses of at least 5 Gy for EBRT, and no other restrictions regarding fractionation schedule or total dose. Exclusion criteria consisted of the presence of regional nodal disease or distant metastases, persisting severe toxicities from previous RT or follow-up shorter than 6 months.
Results
Four hundred and thirty-three patients from 5 centers were included in the current analysis. Overall, 64.2 % and 90.3 % of patients did not report any acuteGU or GI toxicity. No treatment-related deaths were registered. LateG2 or G3 GU toxicity was reported in 16.2 and 4.8 % of patients, respectively. After a median follow-up of 54 months (95 % CI 26–78), 239 biochemical recurrences (55.2 %), 119 radiologically-confirmed regional or distant relapses (27.2 %), and 95 deaths (21.9 %) were recorded, respectively.
Conclusion
Results confirm the safety, feasibility, and efficacy of re-irradiation for prostate cancer, and provide insights about features associated with improved oncological outcomes after treatment.
期刊介绍:
Radiotherapy and Oncology publishes papers describing original research as well as review articles. It covers areas of interest relating to radiation oncology. This includes: clinical radiotherapy, combined modality treatment, translational studies, epidemiological outcomes, imaging, dosimetry, and radiation therapy planning, experimental work in radiobiology, chemobiology, hyperthermia and tumour biology, as well as data science in radiation oncology and physics aspects relevant to oncology.Papers on more general aspects of interest to the radiation oncologist including chemotherapy, surgery and immunology are also published.